A number of investment brokers have recently updated their price targets on shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

05/04/2016 – AMAG Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 40 price target on the stock.

05/04/2016 – AMAG Pharmaceuticals, Inc. was downgraded to “market perform” by analysts at Raymond James.

03/28/2016 – AMAG Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Robert W. Baird. They now have a USD 25 price target on the stock.

03/28/2016 – AMAG Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at Ladenburg Thalmann.

03/28/2016 – AMAG Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Jefferies.

02/18/2016 – AMAG Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Guggenheim. They now have a USD 51 price target on the stock.

01/28/2016 – Northland Securities began new coverage on AMAG Pharmaceuticals, Inc. giving the company a “outperform” rating. They now have a USD 40 price target on the stock.

01/21/2016 – Barclays began new coverage on AMAG Pharmaceuticals, Inc. giving the company a “equal-weight” rating. They now have a USD 32 price target on the stock.

11/19/2015 – AMAG Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Deutsche Bank. They now have a USD 43 price target on the stock.

05/09/2015 – AMAG Pharmaceuticals, Inc. was downgraded to “strong sell” by analysts at Zacks.

05/06/2015 – AMAG Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at JP Morgan. They now have a USD 51 price target on the stock.

03/09/2015 – Cowen began new coverage on AMAG Pharmaceuticals, Inc. giving the company a “outperform” rating. They now have a USD 65 price target on the stock.

01/26/2015 – AMAG Pharmaceuticals, Inc. had its “mkt perform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 42 price target on the stock.

03/03/2014 – AMAG Pharmaceuticals, Inc. was upgraded to “hold” by analysts at Thomson Reuters/Verus.

01/23/2014 – AMAG Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Summer Street. They now have a USD 30 price target on the stock.

The share price of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) was down -1.24% during the last day of trading, with a day high of 20.24. 1967180 shares were traded during the last session.

The stock’s 50 day moving average is 24.30 and its 200 day moving average is 26.51. The stock’s market capitalization is 689.75M. AMAG Pharmaceuticals, Inc. has a 52-week low of 19.35 and a 52-week high of 77.73.

View other investors thoughts on AMAG Pharmaceuticals, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.